RNF43 p.G659fs 通过 PI3K/AKT/mTOR 信号通路和 HLA-E 上调导致 MSI-high 结直肠癌中 NK 细胞功能障碍
RNF43 p.G659fs leads to natural killer cell dysfunction in MSI-high colorectal cancer through PI3K/AKT/mTOR signaling and HLA-E up-regulation.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Intratumoral NKp46(+) natural killer cells are spatially distanced from T and MHC-I(+) cells with prognostic implications in soft tissue sarcoma.
Intratumoral NKp46(+) natural killer cells are spatially distanced from T and MHC-I(+) cells with prognostic implications in soft tissue sarcoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
肿瘤内 NK 细胞在 STS 中具有预后意义,且与 T 细胞相比更靠近 MHC-I-细胞。尽管 NK 细胞和 T 细胞均与 STS 生存改善相关,但它们在 TME 中基于 MHC-I 表达状态的不同分布可作为改善免疫治疗选择的生物标志物。
软组织肉瘤(STS)是一种罕见、异质性强的恶性肿瘤,对新免疫疗法的需求尚未得到满足。TIL(肿瘤浸润淋巴细胞)(TILs)与STS患者的良好预后相关,但自然杀伤(NK)细胞的作用以及TILs与表达MHC-I细胞的空间关系尚缺乏详细表征。
我们使用存档标本和前瞻性收集的标本,通过免疫组织化学(IHC)、流式细胞术和免疫荧光(IF)评估了肿瘤内NK细胞。我们通过多重IF评估了NK细胞和T细胞的空间定位,分析了MHC-I表达状态对NK细胞和T细胞聚集的影响。
肿瘤内NKp46和CD56 dim表达均与总生存期显著改善相关(P=0.05),而CD56bright NK细胞浸润较高则预示预后较差(P=0.05)。肿瘤内NK细胞的存在与CD3 + T细胞呈反比。空间分析显示,NK细胞优先聚集在其他NK细胞附近,而CD3 + T和CD8 + T细胞在该范围内分布稀疏(P<0.0001)。此外,与NK细胞相比,CD3 + T和CD8 + T细胞与MHC-I +细胞的共定位显著更多(P<0.0001)。新辅助放疗后,CD8聚集增加,而新辅助化疗后,TIL聚集总体降低。
Both intratumoral NKp46 and CD56 dim expression were associated with significantly improved overall survival (P=0.05), while higher infiltrates of CD56bright NK cells predicted a worse prognosis (P=0.05). The presence of intratumoral NK cells was inversely proportional to CD3 + T cells. Spatial analyses showed NK cells preferentially clustering close to other NK cells with sparse CD3 + T and CD8 + T cells in range (P<0.0001). Additionally, CD3 + T and CD8 + T cells showed significantly greater co-localization with MHC-I + cells, compared to NK cells (P<0.0001). After neoadjuvant radiotherapy, there was greater CD8 clustering, while after neoadjuvant chemotherapy, there was overall lower TIL clustering.
Intratumoral NK cells are prognostic in STS and localize closer to MHC-I- cells than T cells. Although both NK and T cells are associated with improved survival in STS, their differential distribution in the TME based on MHC-I expression status may serve as a biomarker for improved immunotherapy treatment selection.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。